Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/32210
Title: Dearth of ICD Codes for Complications of Immune Checkpoint Inhibitors Impedes Clinical Care and Research.
Austin Authors: Cheung, Yee-Ming Melody ;Hamnvik, Ole-Petter R;Shariff, Afreen;Gallagher, Emily J
Affiliation: Division of Endocrinology, Diabetes, and Hypertension, Department of Medicine, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA 02115, USA.
Division of Endocrinology, Diabetes, and Hypertension, Department of Medicine, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA 02115, USA.
Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, Duke University School of Medicine, Durham, NC 27708, USA.
Medicine (University of Melbourne)
Issue Date: 9-Feb-2023
Date: 2023
Publication information: Journal of the Endocrine Society 2023; 7(4)
Abstract: Immune checkpoint inhibitors (ICIs) are a rapidly expanding class of targeted therapies effective in the treatment of various cancers. However, while efficacious, ICIs have been associated with treatment complications, namely immune-related adverse events (irAEs). IrAEs of the endocrine system are among the most commonly reported irAEs, but despite their high incidence, standardized disease definitions and endocrine IrAE-specific International Classification of Diseases (ICD) codes remain lacking. This dearth of standardized nomenclature and ICD codes has in many ways impeded both the clinical care of patients and the progress of endocrine irAE-related research. ICD codes are used internationally and are essential for medical claims reporting in the health care setting, and they provide a universal language system for recording, reporting, and monitoring diseases. These codes are also a well-accepted form of electronic health record data capture that facilitates the collection, storage, and sharing of data. Therefore, the lack of standardized disease definitions and ICD codes has been associated with misclassification and suboptimal management of individuals with endocrine irAEs and has also been associated with reduced data availability, comparability, and quality. Harmonized and clinically relevant disease definitions along with the subsequent development of endocrine-irAE-specific ICD codes will provide a systematic approach to understanding the spectrum and burden of endocrine irAE diseases, and will have a positive effect across clinical, public health, and research settings.
URI: https://ahro.austin.org.au/austinjspui/handle/1/32210
DOI: 10.1210/jendso/bvad019
ORCID: 0000-0002-7920-8474
Journal: Journal of the Endocrine Society
Start page: bvad019
PubMed URL: 36819460
ISSN: 2472-1972
Type: Journal Article
Subjects: endocrine immune-related adverse effects
immune checkpoint inhibitors
immunotherapy
international classification of disease
nomenclature
Appears in Collections:Journal articles

Show full item record

Page view(s)

34
checked on Nov 25, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.